(Q41460572)

1 October 2017

1 reference

title

Prescribing in liver disease (English)

1 reference

1 October 2017

J Reichen

1

1 reference

1 October 2017

publication date

1 January 1997

1 reference

1 October 2017

published in

Journal of Hepatology

1 reference

1 October 2017

volume

26 Suppl 1

1 reference

1 October 2017

page(s)

36-40

1 reference

Commentary: a physiological approach to hepatic drug clearance

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Perfusion-limited of plasma drug binding on hepatic drug extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Determinants of drug disposition in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Noninvasive measurement of nutrient portal blood shunting: an experimental study with [14C]ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Assessment of hepatic function with xenobiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

The pharmacokinetics of enalapril in patients with compensated liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Furosemide kinetics and dynamics in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: A randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Lack of vascular hyporesponsiveness to the L-type calcium channel activator, Bay K 8644, in rats with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Impairment of blood pressure control in patients with liver cirrhosis during tilting: study on adrenergic and renin-angiotensin systems

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a post-receptor defect in angiotensin action.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Reduced splanchnic vasoconstriction to angiotensin II in conscious rats with biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Hemodynamic responses to selective blockade of β2- and β1-adrenoceptors in conscious rats with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Renal response to atrial natriuretic peptide in patients with advanced liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Blunted natriuretic response and low blood pressure after atrial natriuretic factor in early cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Blunted systemic, splanchnic, and renal hemodynamic responses to atrial natriuretic peptide in rats with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

The effects of age and liver disease on the disposition and elimination of diazepam in adult man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Clinical effects and metabolism of diazepam in patients with chronic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Association of acetaminophen hepatotoxicity with fasting and ethanol use.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Fulminant hepatitis associated with centrilobular hepatic necrosis in young children

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Reversible acute decrease in renal function by NSAIDs in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Beta-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Grand mal seizures as a complication of treatment with pefloxacin in patients with cirrhosis. A report of three cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Aminoglycoside nephrotoxicity in obstructive jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2982331-8

7 January 2021

10.1016/S0168-8278(97)82331-8

Identifiers

DOI

1 reference

1 October 2017

1 reference